Det virker fortsatt som du snakker om generell klinisk (edit: ikke etter den siste endringen da) praksis hvor dette er avgjørelser tatt av behandlende lege. Men i en klinisk studie er jo dette definert helt fast i protokollen (som vi altså ikke har for INITIUM).
Men i CM-067 så var det altså:
Subjects will be evaluated for tumor response beginning 12 weeks (± 1 week) from randomization and continuing every 6 weeks (± 1 week) for the first 12 months from randomization and every 12 weeks thereafter, until disease progression
https://www.nejm.org/doi/suppl/10.1056/NEJMoa1910836/suppl_file/nejmoa1910836_protocol.pdf
I den relativt ferske RELATIVITY-047 til BMS f.eks. var det:
“Tumor response, according to RECIST, version 1.1 was assessed by blinded independent review at 12 weeks, followed by every 8 weeks up to 52 weeks, and then every 12 weeks until disease progression or treatment discontinuation.”
https://www.nejm.org/doi/full/10.1056/nejmoa2109970
Men anyway, jeg får veldig følelsen at du jobber med dette @HungryAlfred . Stemmer det?
Men hvorfor lurte du egentlig på dette @Laaarsas ? Var det i forhold til de 24mnd?